199 related articles for article (PubMed ID: 31092383)
1. Current management of neuroblastoma and future direction.
Pastor ER; Mousa SA
Crit Rev Oncol Hematol; 2019 Jun; 138():38-43. PubMed ID: 31092383
[TBL] [Abstract][Full Text] [Related]
2. State of the art in immunotherapy of neuroblastoma.
Jabbari P; Hanaei S; Rezaei N
Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
[TBL] [Abstract][Full Text] [Related]
3. The quest to develop an effective therapy for neuroblastoma.
Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
[TBL] [Abstract][Full Text] [Related]
4. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
5. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J; Sondel PM
J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
[TBL] [Abstract][Full Text] [Related]
6. Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.
Rivera Z; Escutia C; Madonna MB; Gupta KH
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239815
[TBL] [Abstract][Full Text] [Related]
7. Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Heczey A; Louis CU
Discov Med; 2013 Dec; 16(90):287-94. PubMed ID: 24333408
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.
Kholodenko IV; Kalinovsky DV; Doronin II; Deyev SM; Kholodenko RV
J Immunol Res; 2018; 2018():7394268. PubMed ID: 30116755
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.
Berger M; VON Schweinitz D
Anticancer Res; 2017 Nov; 37(11):5911-5918. PubMed ID: 29061769
[TBL] [Abstract][Full Text] [Related]
10. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
11. Overview and recent advances in the treatment of neuroblastoma.
Whittle SB; Smith V; Doherty E; Zhao S; McCarty S; Zage PE
Expert Rev Anticancer Ther; 2017 Apr; 17(4):369-386. PubMed ID: 28142287
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms and therapeutic targets in neuroblastoma.
Johnsen JI; Dyberg C; Fransson S; Wickström M
Pharmacol Res; 2018 May; 131():164-176. PubMed ID: 29466695
[TBL] [Abstract][Full Text] [Related]
13. Genetic discoveries and treatment advances in neuroblastoma.
Bagatell R; Cohn SL
Curr Opin Pediatr; 2016 Feb; 28(1):19-25. PubMed ID: 26576010
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
15. Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
Park JR; Bagatell R; London WB; Maris JM; Cohn SL; Mattay KK; Hogarty M;
Pediatr Blood Cancer; 2013 Jun; 60(6):985-93. PubMed ID: 23255319
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of Neuroblastoma: Facts and Hopes.
Anderson J; Majzner RG; Sondel PM
Clin Cancer Res; 2022 Aug; 28(15):3196-3206. PubMed ID: 35435953
[TBL] [Abstract][Full Text] [Related]
17. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy.
Morgenstern DA; Baruchel S; Irwin MS
J Pediatr Hematol Oncol; 2013 Jul; 35(5):337-47. PubMed ID: 23703550
[TBL] [Abstract][Full Text] [Related]
18. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
19. Exosomes: Novel Players of Therapy Resistance in Neuroblastoma.
Richard H; Pokhrel A; Chava S; Pathania A; Katta SS; Challagundla KB
Adv Exp Med Biol; 2020; 1277():75-85. PubMed ID: 33119866
[TBL] [Abstract][Full Text] [Related]
20. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]